Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency

Inclusion Criteria:

* Patient\> 18 years;
* Metastatic or locally advanced non-curable undergoing chemotherapy or lymphoid disease for which chemotherapy is indicated solid cancerous disease;
* Patient for which there are at least 3 cycles or 3 months of chemotherapy;
* Haemoglobin between 8.5 and 11 g / dL;
* Functional martial deficiency defined by a coefficient of transferrin saturation and serum ferritin ≤ 20% between 100 and 800 mg / L;
* Life expectancy\> 3 months;
* ECOG ≤ 2.

Exclusion Criteria:

* Documented hemochromatosis ;
* AST and / or ALT\> 2.5N;
* Renal impairment with Cockcroft clearance \<30 mL / min;
* Vitamin B12 deficiency or folate;
* Hemolysis;
* Infectious disease being untreated;
* Haemorrhagic syndrome related or not with the tumor;
* Hypersensitivity to Ferinject ® or any of the excipients;
* Land atopic asthma or eczema known
* Contraindication to EPO;
* Taking a supplement to oral iron;
* Treatment with EPO within 6 months prior to study entry;
* No transfusion of packed red cells within 15 days before enrollment or randomization in the study;
* Participation in another clinical trial;
* Psychiatric pathology can disrupt the course of treatment or prevent the interpretation of results;
* Pregnant or lactating women;
* Persons deprived of liberty;
* Major subject to a measure of legal protection or unable to consent.